NADH

Category: nucleotide

Aliases: Reduced nicotinamide adenine dinucleotide

Pharmacological Mechanism

Reduced form of NAD⁺ — carries a hydride. Donates electrons to ETC Complex I driving oxidative phosphorylation. Supplemental NADH proposed to enter cells and boost ATP regeneration; evidence is preclinical-heavy with some small CFS / Parkinson's RCTs showing symptomatic improvement. Stability is poor without enteric coating.

Dosing Guidelines

• PO: Typical 10 mg (Range: 5–20 mg)
• SL: Typical 10 mg (Range: 5–20 mg)
• IV: Typical 10 mg (Range: 5–20 mg)

Target Organ Systems

• nervous
• musculoskeletal

Interactions

• NAD⁺ (synergistic): Reduced/oxidised pair; NADH is interconverted with NAD⁺ by every dehydrogenase and ETC Complex I.

Pathways It Modulates

• Oxidative phosphorylation (substrate) — electron donor to complex I

Chemical Identifiers

• PubChem CID: 439153
• Formula: C21H29N7O14P2
• Molecular weight: 665.45 g/mol
• InChIKey: BOPGDPNILDQYTO-NNYOXOHSSA-N
• SMILES: C1C=CN(C=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O